Cyclophilin-A: A potential screening marker for vascular disease in type-2 diabetes

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 8, 2012, Pages 1005-1015

  Ramachandran, Surya ^a   Kartha, C C ^a  

^a RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

Cyclophilin A; Inflammation; Monocytes; Type 2 diabetes; Vascular disease

Indexed keywords

3 NITROTYROSINE; ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLOPHILIN A; CYSTATIN C; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID; FERRITIN; GELATINASE B; HOMOCYSTEINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOPHILIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 6 RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PADGEM PROTEIN; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROGENESIS; ATHEROSCLEROSIS; DIABETIC PATIENT; DISEASE COURSE; ENDOTHELIUM CELL; HUMAN; HYPERGLYCEMIA; INFLAMMATORY CELL; INSULIN RESISTANCE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SCREENING; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CYCLOPHILIN A; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MODELS, CARDIOVASCULAR; MONOCYTES; REACTIVE OXYGEN SPECIES; RISK FACTORS;

EID: 84864231340     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y2012-038     Document Type: Review

References (93)

1. Abe, J., and Berk, B.C. 1998. Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Trends Cardiovasc. Med. 8(2): 59-64. doi:10.1016/S1050-1738(97)00133-3. PMID:21235913.
2. Alexander, R.W. 1995. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension, 25(2): 155-161. PMID:7843763.
3. Alpert, E., Gruzman, A., Totary, H., Kaiser, N., Reich, R., and Sasson, S. 2002. A natural protective mechanism against hyperglycaemia in vascular endothelial and smooth-muscle cells: role of glucose and 12-hydroxyeicosatetraenoic acid. Biochem. J. 362(2): 413-422. doi:10.1042/0264-6021:3620413. PMID: 11853550.
4. Aronson, D., Bartha, P., Zinder, O., Kerner, A., Shitman, E., Markiewicz, W., et al. 2004. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet. Med. 21(1): 39-44. doi:10.1046/j.1464-5491.2003.01084.x. PMID:14706052.
5. 2-in vascular smooth muscle cells. Circ. Res. 77(1): 29-36. PMID:7540516.
6. Beckman, J.A., Goldfine, A.B., Gordon, M.B., and Creager, M.A. 2001. Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation, 103(12): 1618-1623. PMID:11273987.
7. Billich, A., Winkler, G., Aschauer, H., Rot, A., and Peichl, P. 1997. Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis. J. Exp. Med. 185(5): 975-980. doi:10.1084/jem.185.5.975. PMID:9120404.
8. Blackburn, G.L. 2001. Pasteur's Quadrant and malnutrition. Nature, 409(6818): 397-401. doi:10.1038/35053187. PMID:11201754.
9. Blankenberg, S., and Yusuf, S. 2006. The inflammatory hypothesis: any progress in risk stratification and therapeutic targets. Circulation, 114(15): 1557-1560. doi:10.1161/CIRCULATIONAHA.106. 652081. PMID:17030701.
10. Boden, G. 1999. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc. Assoc. Am. Physicians, 111(3): 241-248. doi:10.1046/j.1525-1381.1999.99220.x. PMID:10354364.
11. Bruno, G., Merletti, F., Bargero, G., Melis, D., Masi, I., Ianni, A., et al. 2008. Changes over time in the prevalence and quality of care of type 2 diabetes in Italy: the Casale Monferrato Surveys, 1988 and 2000. Nutr. Metab. Cardiovasc. Dis. 18(1): 39-45. doi:10. 1016/j.numecd.2006.08.007. PMID:17321119.
12. Castelli, W.P. 1996. Lipids, risk factors and ischaemic heart disease. Atherosclerosis, 124(Suppl.): S1-S9. doi:10.1016/0021-9150(96) 05851-0. PMID:8831910.
13. Chapman, C.M.L., Beilby, J.P., McQuillan, B.M., Thompson, P.L., and Hung, J. 2004. Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke, 35(7): 1619-1624. doi:10.1161/01.STR. 0000130857.19423.ad. PMID:15155967.
14. Clempus, R.E., and Griendling, K.K. 2006. Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc. Res. 71(2): 216-225. doi:10.1016/j.cardiores.2006.02.033. PMID:16616906.
15. de Lemos, J.A., Morrow, D.A., Blazing, M.A., Jarolim, P., Wiviott, S. D., Sabatine, M.S., et al. 2007. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes. Results from the A to Z Trial. J. Am. Coll. Cardiol. 50(22): 2117-2124. doi:10.1016/j.jacc.2007.06.057. PMID:18036447.
16. de Rekeneire, N., Peila, R., Ding, J., Colbert, L.H., Visser, M., Shorr, R.I., et al. 2006. Diabetes, hyperglycemia, and inflammation in older individuals: the Health, Aging and Body Composition study. Diabetes Care, 29(8): 1902-1908. doi:10.2337/dc05-2327. PMID: 16873800.
17. Devaraj, S., Xu, D.Y., and Jialal, I. 2003. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation, 107(3): 398-404. doi:10.1161/01.CIR.0000052617.91920.FD. PMID:12551862.
18. Dichtl, W., Nilsson, L., Goncalves, I., Ares, M.P., Banfi, C., Calara, F., et al. 1999. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ. Res. 84(9): 1085-1094. PMID:10325246.
19. Dresner, A., Laurent, D., Marcucci, M., Griffin, M.E., Dufour, S., Cline, G.W., et al. 1999. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 103(2): 253-259. doi:10.1172/JCI5001. PMID:9916137.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive summary of the 3rd Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285 (19): 2486-2497. doi:10.1001/jama.285.19.2486. PMID: 11368702.
21. Fischer, G., Wittmann-Liebold, B., Lang, K., Kiefhaber, T., and Schmid, F.X. 1989. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature, 337(6206): 476-478. doi:10.1038/337476a0. PMID:2492638.
22. Fujimoto, W.Y. 2000. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am. J. Med. 108(4 Suppl. 6a): 9S-14S. doi:10.1016/S0002-9343(00)00337-5. PMID: 10764845.
23. Fukumoto, H., Naito, Z., Asano, G., and Aramaki, T. 1998. Immunohistochemical and morphometric evaluations of coronary atherosclerotic plaques associated with myocardial infarction and diabetes mellitus. J. Atheroscler. Thromb. 5(1): 29-35. PMID: 10077455.
24. Galat, A. 1993. Peptidylproline cis-trans-isomerases: immunophilins. Eur. J. Biochem. 216(3): 689-707. doi:10.1111/j.1432-1033.1993. tb18189.x. PMID:8404888.
25. Griendling, K.K., Minieri, C.A., Ollerenshaw, J.D., and Alexander, R.W. 1994. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74(6): 1141-1148. PMID:8187280.
26. Haffner, S.M., Stern, M.P., Hazuda, H.P., Mitchell, B.D., and Patterson, J.K. 1990. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA, 263(21): 2893-2898. doi:10.1001/jama.1990.03440210043030. PMID: 2338751.
27. Handschumacher, R.E., Harding, M.W., Rice, J., Drugge, R.J., and Speicher, D.W. 1984. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science, 226(4674): 544-547. doi:10. 1126/science.6238408. PMID:6238408.
28. Harding, M.W., Handschumacher, R.E., and Speicher, D.W. 1986. Isolation and amino acid sequence of cyclophilin. J. Biol. Chem. 261(18): 8547-8555. PMID:3522572.
29. Hattori, Y., Hattori, S., Sato, N., and Kasai, K. 2000. High-glucoseinduced nuclear factor kappaB activation in vascular smooth muscle cells. Cardiovasc. Res. 46(1): 188-197. doi:10.1016/S0008-6363(99)00425-3. PMID:10727667.
30. Herder, C., Muller-Scholze, S., Rating, P., Koenig, W., Thorand, B., Haastert, B., et al. 2006. Systemicmonocyte chemoattractant protein-1 concentrations are independent of type 2 diabetes or parameters of obesity: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Eur. J. Endocrinol. 154(2): 311-317. doi:10.1530/eje.1.02090. PMID:16452546.
31. Hink, U., Li, H., Mollnau, H., Oelze, M., Matheis, E., Hartmann, M., et al. 2001. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 88(2): E14-E22. PMID:11157681.
32. Hotamisligil, G.S. 2004. Inflammation, TNFalpha, and insulin resistance. In Diabetes mellitus: a fundamental and clinical text. Edited by D.T.S. LeRoith and J.M. Olefsky. 3rd ed. Lippincott, Williams and Wilkins, New York, N.Y. pp. 953-962.
33. Hu, F.B., Meigs, J.B., Li, T.Y., Rifai, N., and Manson, J.E. 2004. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes, 53(3): 693-700. doi:10.2337/diabetes.53.3.693. PMID:14988254.
34. Hu, S., Arellano, M., Boontheung, P., Wang, J., Zhou, H., Jiang, J., et al. 2008. Salivary proteomics for oral cancer biomarker discovery. Clin. Cancer Res. 14(19): 6246-6252. doi:10.1158/1078-0432. CCR-07-5037. PMID:18829504.
35. Inoguchi, T., Li, P., Umeda, F., Yu, H.Y., Kakimoto, M., Imamura, M., et al. 2000. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes, 49(11): 1939-1945. doi:10.2337/diabetes.49.11. 1939. PMID:11078463.
36. Inoue, T., and Node, K. 2009. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ. J. 73(4): 615-621. doi:10.1253/circj.CJ-09-0059. PMID:19282604.
37. Jin, Z.-G., Melaragno, M.G., Liao, D.-F., Yan, C., Haendeler, J., Suh, Y.-A., et al. 2000. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ. Res. 87(9): 789-796. PMID: 11055983.
38. Jin, Z.G., Lungu, A.O., Xie, L., Wang, M., Wong, C., and Berk, B.C. 2004. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler. Thromb. Vasc. Biol. 24(7): 1186-1191. doi:10.1161/01.ATV.0000130664.51010.28. PMID: 15130913.
39. Kaiser, N., Yuli, M., Uckaya, G., Oprescu, A.I., Berthault, M.F., Kargar, C., et al. 2005. Dynamic changes in beta-cell mass and pancreatic insulin during the evolution of nutrition-dependent diabetes in Psammomys obesus: impact of glycemic control. Diabetes, 54(1): 138-145. doi:10.2337/diabetes.54.1.138. PMID: 15616021.
40. Karagiannis, G.S., Pavlou, M.P., and Diamandis, E.P. 2010. Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Mol. Oncol. 4(6): 496-510. doi:10.1016/j.molonc. 2010.09.001. PMID:20934395.
41. Kelley, D.E., and Simoneau, J.A. 1994. Impaired free fatty acid utilization by skeletal muscle in non-insulin-dependent diabetes mellitus. J. Clin. Invest. 94(6): 2349-2356. doi:10.1172/JCI117600. PMID:7989591.
42. Khaw, K.T., Wareham, N., Luben, R., Bingham, S., Oakes, S., Welch, A., and Day, N. 2001. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ, 322(7277): 15-18. doi:10.1136/bmj.322.7277.15. PMID:11141143.
43. Kim, H., Kim, W.J., Jeon, S.T., Koh, E.M., Cha, H.S., Ahn, K.S., and Lee, W.-H. 2005. Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. Clin. Immunol. 116(3): 217-224. doi:10.1016/j.clim. 2005.05.004. PMID:15993649.
44. King, D.E., Mainous, A.G., III, Buchanan, T.A., and Pearson, W.S. 2003. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care, 26(5): 1535-1539. doi:10.2337/diacare. 26.5.1535. PMID:12716818.
45. Kinlay, S., Libby, P., and Ganz, P. 2001. Endothelial function and coronary artery disease. Curr. Opin. Lipidol. 12(4): 383-389. doi:10.1097/00041433-200108000-00003. PMID:11507322.
46. Kolberg, J.A., Jorgensen, T., Gerwien, R.W., Hamren, S., McKenna, M.P., Moler, E., et al. 2009. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the inter99 cohort. Diabetes Care, 32(7): 1207-1212. doi:10.2337/dc08-1935. PMID: 19564473.
47. Langdown, M.L., Holness, M.J., and Sugden, M.C. 2003. Effects of prenatal glucocorticoid exposure on cardiac calreticulin and calsequestrin protein expression during early development and in adulthood. Biochem. J. 371(1): 61-69. doi:10.1042/BJ20021771. PMID:12519072.
48. Lee, J. 2010. Role of cyclophilin A during oncogenesis. Arch. Pharm. Res. 33(2): 181-187. doi:10.1007/s12272-010-0200-y. PMID: 20195816.
49. Libby, P. 2001. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation, 104(3): 365-372. PMID: 11457759.
50. Libby, P. 2002. Inflammation in atherosclerosis. Nature, 420(6917): 868-874. doi:10.1038/nature01323. PMID:12490960.
51. Libby, P., and Theroux, P. 2005. Pathophysiology of coronary artery disease. Circulation, 111(25): 3481-3488. doi:10.1161/CIRCULATIONAHA.105.537878. PMID:15983262.
52. Lindström, J., and Tuomilehto, J. 2003. The diabetes risk score: A practical tool to predict type 2 diabetes risk. Diabetes Care, 26(3): 725-731. doi:10.2337/diacare.26.3.725. PMID:12610029.
53. Lyssenko, V., Jonsson, A., Almgren, P., Pulizzi, N., Isomaa, B., Tuomi, T., et al. 2008. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N. Engl. J. Med. 359(21): 2220-2232. doi:10.1056/NEJMoa0801869. PMID:19020324.
54. Marks, A.R. 1996. Cellular functions of immunophilins. Physiol. Rev. 76(3): 631-649. PMID:8757784.
55. Martinovic, I., Abegunewardene, N., Seul, M., Vosseler, M., Horstick, G., Buerke, M., et al. 2005. Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ. J. 69(12): 1484-1489. doi:10.1253/circj.69.1484. PMID:16308496.
56. McMillan, D.E. 1989. Increased levels of acute-phase serum proteins in diabetes. Metabolism, 38(11): 1042-1046. doi:10.1016/0026-0495(89)90038-3. PMID:2478861.
57. Meigs, J.B., Nathan, D.M., Wilson, P.W., Cupples, L.A., and Singer, D.E. 1998. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann. Intern. Med. 128(7): 524-533. PMID: 9518396.
58. Meigs, J.B., Hu, F.B., Rifai, N., and Manson, J.E. 2004. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA, 291(16): 1978-1986. doi:10.1001/jama.291.16.1978. PMID:15113816.
59. L-arginine-nitric oxide pathway. N. Engl. J. Med. 329(27): 2002-2012. doi:10.1056/NEJM199312303292706. PMID:7504210.
60. Nesher, R., Gross, D.J., Donath, M.Y., Cerasi, E., and Kaiser, N. 1999. Interaction between genetic and dietary factors determines beta-cell function in Psammomys obesus, an animal model of type 2 diabetes. Diabetes, 48(4): 731-737. doi:10.2337/diabetes.48.4. 731. PMID:10102688.
61. Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S.-i., Matsumura, T., Kaneda, Y., et al. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 404(6779): 787-790. doi:10.1038/35008121. PMID: 10783895.
62. Nugent, A.G., McGurk, C., Hayes, J.R., and Johnston, G.D. 1996. Impaired vasoconstriction to endothelin 1 in patients with NIDDM. Diabetes, 45(1): 105-107. doi:10.2337/diabetes.45.1. 105. PMID:8522053.
63. Omar, H.A., Cherry, P.D., Mortelliti, M.P., Burke-Wolin, T., and Wolin, M.S. 1991. Inhibition of coronary artery superoxide dismutase attenuates endothelium-dependent and-independent nitrovasodilator relaxation. Circ. Res. 69(3): 601-608. PMID: 1651814.
64. Panicker, S.R., and Kartha, C.C. 2010. Curcumin attenuates glucoseinduced monocyte chemoattractant protein-1 synthesis in aortic endothelial cells by modulating the nuclear-factor kappaB pathway. Pharmacology, 85(1): 18-26. doi:10.1159/000262325. PMID:19955845.
65. Piemonti, L., Calori, G., Mercalli, A., Lattuada, G., Monti, P., Garancini, M.P., et al. 2003. Fasting plasma leptin, tumor necrosis factor-a receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucoseintolerant women: impact on cardiovascular mortality. Diabetes Care, 26(10): 2883-2889. doi:10.2337/diacare.26.10.2883. PMID: 14514596.
66. Pushkarsky, T., Zybarth, G., Dubrovsky, L., Yurchenko, V., Tang, H., Guo, H., et al. 2001. CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A. Proc. Natl. Acad. Sci. U.S.A. 98(11): 6360-6365. doi:10.1073/pnas.111583198. PMID:11353871.
67. Radomski, M.W., Palmer, R.M., and Moncada, S. 1987. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem. Biophys. Res. Commun. 148(3): 1482-1489. doi:10.1016/S0006-291X(87)80299-1. PMID:2825688.
68. Ramachandran, S., Venugopal, A., Satisha, K., Prathapachandran, N.S., Mullasari, A., Pillai, M.R., and Kartha, C.C. 2011. Can circulating monocytes be used to predict risk of macrovascular disease in type 2 diabetes? Exp. Clin. Cardiol. 16(Suppl. A): 23A (Abstract). PMC3206546.
69. Ridker, P.M. 2003. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation, 107(3): 363-369. doi:10.1161/01.CIR.0000053730.47739.3C. PMID: 12551853.
70. Ridker, P.M., Rifai, N., Rose, L., Buring, J.E., and Cook, N.R. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347(20): 1557-1565. doi:10.1056/NEJMoa021993. PMID:12432042.
71. Rifai, N., Gillette, M.A., and Carr, S.A. 2006. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24(8): 971-983. doi:10.1038/nbt1235. PMID:16900146.
72. Salomaa, V., Havulinna, A., Saarela, O., Zeller, T., Jousilahti, P., Jula, A., et al. 2010. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE, 5(4): e10100. doi:10. 1371/journal.pone.0010100. PMID:20396381.
73. Sarkar, R., Meinberg, E.G., Stanley, J.C., Gordon, D., andWebb, R.C. 1996. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ. Res. 78(2): 225-230. PMID: 8575065.
74. Sasson, S., Kaiser, N., Dan-Goor, M., Oron, R., Koren, S., Wertheimer, E., et al. 1997. Substrate autoregulation of glucose transport: hexose 6-phosphate mediates the cellular distribution of glucose transporters. Diabetologia, 40(1): 30-39. doi:10.1007/s001250050639. PMID:9028715.
75. Sattar, N., Wannamethee, S.G., and Forouhi, N.G. 2008. Novel biochemical risk factors for type 2 diabetes: Pathogenic insights or prediction possibilities? Diabetologia, 51(6): 926-940. doi:10. 1007/s00125-008-0954-7. PMID:18392804.
76. Schalkwijk, C.G., Poland, D.C., van Dijk, W., Kok, A., Emeis, J.J., Dräger, A.M., et al. 1999. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia, 42(3): 351-357. doi:10.1007/s001250051162. PMID:10096789.
77. Sela-Brown, A., Silver, J., Brewer, G., and Naveh-Many, T. 2000. Identification of AUF1 as a parathyroid hormone mRNA 3′-untranslated region-binding protein that determines parathyroid hormone mRNA stability. J. Biol. Chem. 275(10): 7424-7429. doi:10.1074/jbc.275.10.7424. PMID:10702317.
78. Shanmugam, N., Reddy, M.A., Guha, M., and Natarajan, R. 2003. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes, 52(5): 1256-1264. doi:10.2337/diabetes.52.5.1256. PMID:12716761.
79. Sherry, B., Yarlett, N., Strupp, A., and Cerami, A. 1992. Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc. Natl. Acad. Sci. U.S.A. 89(8): 3511-3515. doi:10.1073/pnas.89.8.3511. PMID:1565646.
80. Soinio, M., Marniemi, J., Laakso, M., Lehto, S., and Rönnemaa, T. 2006. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care, 29(2): 329-333. doi:10.2337/diacare.29.02.06.dc05-1700. PMID:16443882.
81. Stehouwer, C.D.A., Gall, M.A., Twisk, J.W.R., Knudsen, E., Emeis, J.J., and Parving, H.H. 2002. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes, 51(4): 1157-1165. doi:10.2337/diabetes.51.4.1157. PMID:11916939.
82. Sun, J., and Hemler, M.E. 2001. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 61(5): 2276-2281. PMID: 11280798.
83. Suzuki, L.A., Poot, M., Gerrity, R.G., and Bornfeldt, K.E. 2001. Diabetes accelerates smooth muscle accumulation in lesions of atherosclerosis: lack of direct growth promoting effects of high glucose levels. Diabetes, 50(4): 851-860. doi:10.2337/diabetes.50. 4.851. PMID:11289052.
84. Tesfamariam, B., Brown, M.L., and Cohen, R.A. 1991. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J. Clin. Invest. 87(5): 1643-1648. doi:10.1172/JCI115179. PMID:2022734.
85. Tsimikas, S., Willerson, J.T., and Ridker, P.M. 2006. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J. Am. Coll. Cardiol. 47(8 Suppl.): C19-C31. doi:10.1016/j.jacc.2005.10.066. PMID: 16631506.
86. Uittenbogaard, A., Ying, Y., and Smart, E.J. 1998. Characterization of a cytosolic heat-shock protein-caveolin chaperone complex: Involvement in cholesterol trafficking. J. Biol. Chem. 273(11): 6525-6532. doi:10.1074/jbc.273.11.6525. PMID:9497388.
87. Wang, L., Wang, C.H., Jia, J.F., Ma, X.K., Li, Y., Zhu, H.B., et al. 2010. Contribution of cyclophilin A to the regulation of inflammatory processes in rheumatoid arthritis. J. Clin. Immunol. 30(1): 24-33. doi:10.1007/s10875-009-9329-1. PMID:19789967.
88. Williams, S.B., Cusco, J.A., Roddy, M.A., Johnstone, M.T., and Creager, M.A. 1996. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 27(3): 567-574. doi:10.1016/0735-1097(95)00522-6. PMID:8606266.
89. Wilson, P.W., Meigs, J.B., Sullivan, L., Fox, C.S., Nathan, D.M., and D'Agostino, R.B., Sr. 2007. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch. Intern. Med. 167(10): 1068-1074. doi:10.1001/archinte.167. 10.1068. PMID:17533210.
90. Xu, Q., Leiva, M.C., Fischkoff, S.A., Handschumacher, R.E., and Lyttle, C.R. 1992. Leukocyte chemotactic activity of cyclophilin. J. Biol. Chem. 267(17): 11968-11971. PMID:1601866.
91. Yang, Y., Lu, N., Zhou, J., Chen, Z.N., and Zhu, P. 2008. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford), 47(9): 1299-1310. doi:10. 1093/rheumatology/ken225. PMID:18567920.
92. Zeiher, A.M., Fisslthaler, B., Schray-Utz, B., and Busse, R. 1995. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ. Res. 76(6): 980-986. PMID:7758169.
93. Zimmet, P.Z. 1999. Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia, 42(5): 499-518. doi:10. 1007/s001250051188. PMID:10333041.